Eli Lilly and Company (NYSE:LLY) Given New $1,161.00 Price Target at Guggenheim

Eli Lilly and Company (NYSE:LLY) had its price objective lowered by Guggenheim from $1,163.00 to $1,161.00 in a research report report published on Tuesday morning, MarketBeat.com reports. The firm currently has a buy rating on the stock.

LLY has been the subject of several other reports. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Five analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Trading Up 0.2%

Shares of Eli Lilly and Company stock opened at $1,040.95 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock’s 50 day simple moving average is $1,053.86 and its 200-day simple moving average is $875.14. The stock has a market cap of $984.09 billion, a P/E ratio of 50.93, a P/E/G ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the company. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. KFG Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 7.3% in the second quarter. KFG Wealth Management LLC now owns 457 shares of the company’s stock valued at $356,000 after purchasing an additional 31 shares during the period. IronOak Wealth LLC. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $2,032,000. Finally, Lederer & Associates Investment Counsel CA grew its position in Eli Lilly and Company by 8.6% in the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 2,755 shares of the company’s stock valued at $2,148,000 after buying an additional 217 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s sofetabart mipitecan for certain platinum‑resistant ovarian cancers — a meaningful validation for Lilly’s oncology pipeline that diversifies revenue beyond GLP‑1 drugs and could accelerate development/partnering value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: Phase results: Lilly’s Taltz combined with Zepbound showed superior results in a landmark psoriatic‑arthritis trial — suggests label expansion and additional commercial upside for existing franchises. Eli Lilly’s Taltz and Zepbound combo delivers superior results
• Positive Sentiment: Analyst/media bullishness: Several outlets (MarketBeat, The Motley Fool) highlight Lilly as a top play in 2026 because Zepbound and Mounjaro drive rapid growth and the company has late‑stage assets (Alzheimer’s, oncology, CV) that could sustain upside. That framing supports multiple expansion narratives. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
• Positive Sentiment: Longer‑term growth thesis reinforced: The Motley Fool argues 2026 could be “the year of Eli Lilly,” pointing to the company’s weight‑loss portfolio (recent quarter ~ $10B) and upcoming catalysts — a narrative that attracts growth investors. Prediction: 2026 Will Be the Year of Eli Lilly
• Neutral Sentiment: Analyst note: Guggenheim trimmed its price target slightly (from $1,163 to $1,161) but kept a “buy” rating — a minor technical change that maintains analyst bullishness and implies continued upside from current levels. LLY price target lowered by Guggenheim
• Neutral Sentiment: Takeover speculation calmed: Reports that Lilly might bid for Abivax circulated, but Abivax’s CEO dismissed the rumors as “noise,” removing an M&A upside narrative (so neutral-to-cooling for any takeover-driven pop). Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
• Neutral Sentiment: Industry comparison pieces (Zacks, Blockonomi) reiterate Lilly’s strength from Mounjaro/Zepbound and note an oral GLP‑1 near approval — these are context pieces that support the growth story but also flag competitive dynamics to watch. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Negative Sentiment: Competitive risk: Novo Nordisk’s new oral Wegovy pill showed very fast initial prescriptions after launch, and analysts note rising competition as oral formulations and other entrants scale — a development that could pressure Lilly’s market share and future growth if its oral GLP‑1 underperforms or is delayed. Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.